Podcasts about arsi

Christian Gustafsson och Jesper Hallberg är tillbaka i etern. I dag med IKO-sportchefen Arsi Piispanen som gäst. Dessutom gås alla rykten i genom och ett embryo till ett lagbygge pusslas ihop. Liam Hawel till Kalmar? Hampus Plato? Joel Svensson? Var hittar man spets? När börjar Arsi presentera spelare

U ovoj epizodi Digitalk podcasta ponovo uplovljavamo u vode ljudskih resursa, ali i People Ops funkcije, pričamo o tome koji su danas najveći izazovi HR profesionalaca i odeljenja u kompanijama, kao i koji su to izazovi sa HR strane kada inostrane kompanije dođu u Srbiju i treba da organizuju lokalne kancelarije. Uz dosta detalja iz HR sveta, otkrivamo i jednu veoma zanimljivu metodologiju koja HR stručnjacima pomaže u rešavanju širokog spektra problema, a u pitanju je Lego Serious Play metodologija. O svemu ovome pričali smo sa Milicom Arsić, konsultantkinjom iz oblasti HR-a i People OPS-a, i sertifikovanom fasilitatorkom metodologije Lego Serious Play. Milica Arsić, HR & People Ops konsultantkinja, Lego Serious Play fasilitatorka https://www.linkedin.com/in/milicakosuticarsic/ Teme u epizodi: - Uvod & predstavljanje - Milicin profesionalni razvojni put - Kako uploviti u HR vode? - Današnja uloga HR-a i People Ops timova - Izazovi vođenja kancelarija u Srbiji - Uloga inovacija u HR-u i razvoju zaposlenih - Šta je Lego Serious Play (LSP) metodologija? - Milicina poruka za kraj Prijavite se na naš YouTube kanal: https://bit.ly/3uWtLES Posetite naš sajt i prijavite se na našu mailing listu - https://www.digitalk.rs Pratite DigiTalk.rs na društvenim mrežama: Facebook: https://www.facebook.com/Digitalk.rs Instagram: https://www.instagram.com/digitalk.rs/ Linkedin: https://www.linkedin.com/company/digitalkrs Veliku zahvalnost dugujemo kompanijama koje su prepoznale kvalitet onoga što radimo i odlučile da nas podrže i daju nam vetar u leđa: Partneri podkasta: - Raiffeisen banka - https://www.raiffeisenbank.rs/ Digitalne usluge Raiffeisen banke koje preporučujemo za mala i srednja preduzeća: https://bit.ly/40yAeHw - Kompanija NIS - https://www.nis.rs/ - Ananas - https://ananas.rs/ - kompanija Idea - https://online.idea.rs/ Prijatelj podkasta: - PerformLabs - https://performlabs.agency/ Oslobodite pun potencijal svog digitalnog marketinga! Optimizujte svoje kampanje i postignite maksimalne rezultate uz Performlabs. - BiVits ACTIVA Brain Level Up Booster - https://bivits.com/proizvod/brain-level-up/ Kada želiš da živiš i radiš na višem nivou, uzmi BiVits Brain Level Up za više energije i bolju koncentraciju tokom dana! - Izdavačka kuća Finesa - https://www.finesa.edu.rs/ U ovoj epizodi podelićemo dve knjige "Izgradi" izdavačke kuće Finesa onima koji budu najbrži i najkreativniji sa komentarima, a možete nam slobodno pisati i na info@digitalk.rs i direktno nam uputiti komentar, sugestiju ili primedbu. Takođe, svi oni koji na Finesinom websajtu poruče knjige i unesu promo kod digitalk dobiće 10% popusta na već snižene cene izdanja na sajtu: https://www.finesa.edu.rs/

Christian Gustafsson och Jesper Hallberg är tillbaka i etern. Den här gången om: • Arsi Piispanen – IK:s nya sportchef. Vi ger råd! • Genomgång av tabellen • Slutspelet: vi simulerar – så går det i alla matcher • Alsenfelt • Ordförandens ord – vad betyder "mandat"? • Dessutom, ett långt segment om faxen, overheadapparaten, internetkaféerna och USA:s trupp i VM 94

Croația a recepționat primele 6 avioane de luptă Rafale din Franța, din cele 12 care trebuie să sosească până în 2026, ca parte unui contract de 1,3 miliarde de euro semnat între cele două țări. Între timp, Ambasada americană de la Sarajevo critică primirea călduroasă înapoi la serviciu a doi șefi de rang înalt din poliția Federației Bosnia și Herzegovina după ce au fost arestați 48 de ore sub suspiciunea că sunt apropiați ai unui periculos traficant de droguri bosniac poreclit și Escobar al Europei. Diplomații spun că polițiștii nu au fost condamnați, dar sunt în continuare suspecți. Revista presei Europa Plus: Șase avioane de luptă franceze Rafale au sosit în Croația, citim pe siteul 24sata.hr. Croatia va cheltui 1,13 miliarde de euro pentru achiziționarea a 12 astfel de avioane din Franța până în 2026.Avioanele „au fost aduse de piloți croați care s-au antrenat pentru manevrarea lor timp de 15 luni. Avioanele au sosit la doi ani și cinci luni după semnarea unui contract cu Franța.Acesta este un pas important către modernizarea și consolidarea Forțelor Aeriene Croate în ceea ce privește protecția spațiului aerian - un factor cheie în menținerea securității Croației în viitor, precum și în consolidarea capacității generale de luptă a armatei croate. De asemenea, achiziția acestor avioane simbolizează cooperarea puternică dintre Croația și alianța NATO în menținerea în comun a păcii, stabilității și securității, mai comentează jurnaliștii croați.Polițiști bosniaci suspectați că fac parte din cercul intim al ”Escobarului” Europei„Este șocant faptul că ministrul de Interne al Federației Bosniei Herțegovina sărbătorește revenirea la muncă a ofițerilor de poliție de rang înalt care au fost arestați sub suspiciunea de infracțiuni grave,” a anunțat Ambasada Statelor Unite în Bosnia și Herțegovina. Diplomații americani fac referire la mai mulți polițiști arestați timp de 48 de ore din cauza suspiciunilor că fac parte din cercul intim al lui Edin Gačanin pe care autoritățile americane îl consideră „unul dintre cei mai mari traficanți de droguri din lume”. Gačanin mai este poreclit și Escobar al Europei.Ministrul Afacerilor Interne al Federației Bosniei și Herțegovinei, Ramo Isak, i-a salutat oficial pe Vahidin Munjić, director interimar al Administrației Federale a Poliției, și pe Mustafa Selmanović, comandantul Poliției Speciale, precizează slobodnaevropa.org, Europa Liberă în limba bosniacă.Ambasada Americană a scris pe X că acești polițiști au dreptul să se apere în instanță, dar că acuzațiile împotriva lor nu sunt ceva de sărbătorit. Ambasada Statelor Unite adaugă că întoarcerea la locul de muncă a polițiștilor cercetați nu este în conformitate cu angajamentul față de statul de drept.23 de persoane au fost arestate în Bosnia și Herțegovina, pe 22 aprilie, sub acuzația de crimă organizată și spălare de bani.Cât costă de fapt EXPO 2027 organizat de Serbia?Publicația danas.rs scrie despre costurile proiectului EXPO 2027 care s-ar fi redus, „peste noapte” de la 2,5 la 1,2 miliarde de euro.„Proiectul EXPO 2027, încă de la decizia de a fi atribuit țării noastre, are câteva necunoscute, iar una dintre cele mai mari este cât va costa această expoziție și ce vor include aceste costuri.”„Publicului îi este încă neclar unde se termină proiectul EXPO 2027 și unde încep alte proiecte planificate în viziunea ”Saltul spre viitor – Serbia 2027”. Singurul lucru pe care îl știm este că statul plănuiește o investiție de aproximativ 18 miliarde de euro pentru toate acestea.”Pe de altă parte, Milojko Arsić, profesor la Facultatea de Economie din Belgrad, consideră că este foarte ciudat că prețul acestui proiect a fost acum redus cu mai mult de jumătate. El subliniază că oficialii guvernamentali sunt obligați să prezinte în detaliu cetățenilor structura costurilor.„Trebuie să spună dacă, de exemplu, aceste costuri vor fi finanțate mai întâi prin împrumuturi, dar că aceste împrumuturi vor fi rambursate prin impozite, adică din fondurile cetățenilor. Trebuie să propună o estimare orientativă a costului și a ceea ce este inclus în acest proiect”, explică Arsić.OSCE: Muntenegru face progrese privind procesul electoral„Misiunea OSCE în Muntenegru rămâne dedicată dezvoltării capacităților autorităților electorale pentru organizarea  alegerilor în conformitate cu obligațiile și principiile organizației și va asista Comisia Electorală de Stat  în modificarea legilor electorale,” relatează rtcg.me. Publicația citează raportul Misiunii OSCE potrivit căruia „administrația, educația alegătorilor și accesibilitatea (la vot, n.r.) au fost îmbunătățite, obiectivele pentru care (OSCE, n.r.) lucrează cu Comisia Electorală de Stat și Comisiile Electorale Municipale.”Potrivit raportului OSCE, autoritățile muntenegrene au depus eforturi și înainte de alegerile prezidențiale de anul trecut pentru a informa alegătorii și pentru a îmbunătăți activitatea membrilor consiliilor electorale.„Cu ajutorul Misiunii, s-a desfășurat o campanie națională de zece zile pentru educarea a alegătorilor de zece zile, precum și pentru instruirea membrilor consiliilor electorale”, mai spune raportul OSCE citat de publicația muntenegreană. Europa Plus este un proiect RFI România realizat în parteneriat cu Agenția Universitară a Francofoniei

On est sur du bourrin, aujourd'hui, dès le nom du jeu : UltraKill, un jeu principalement créé par une personne, le finlandais Arsi Patala plus connu sous le pseudonyme Hakita. C'est lui qui compose la quasi totalité de la bande son du jeu sous un autre alias, Heaven Pierce Her. Le jeu est encore en développement, il sort chapitre par chapitre depuis 2020, et la musique aussi, ce qui fait que la bande son est, pour le moment, divisée en cinq albums, et je vais ici uniquement parler du premier sorti. Ce jeu s'inscrit dans un genre très particulier, appelé avec affection le "boomer shooter", jeu de tir de boomers.

A new research paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.” Reduced SIRT2 deacetylation and increased p300 acetylation activity leads to a concerted mechanism of hyperacetylation at specific histone lysine sites (H3K9, H3K14, and H3K18) in castration-resistant prostate cancer (CRPC). In this new study, researchers Mikolaj Filon, Bing Yang, Tanaya A. Purohit, Jennifer Schehr, Anupama Singh, Marcelo Bigarella, Peter Lewis, John Denu, Joshua Lang, and David F. Jarrard from the University of Wisconsin examined whether circulating tumor cells (CTCs) identify patients with altered p300/CBP acetylation. “In the current study, employing a novel Exclusion-based Sample Preparation (ESP) technology (9) (Supplementary Figure 1) to isolate CTCs, we evaluated p300 activity, SIRT2 expression and H3K18 acetylation in CTCs in a series of patients with sensitivity or resistance to ADT.” CTCs were isolated from 13 advanced PC patients using Exclusion-based Sample Preparation (ESP) technology. Bound cells underwent immunofluorescent staining for histone modifying enzymes (HMEs) of interest and image capture with NIS-Elements software. Using the cBioPortal PCF/SU2C dataset, the response of CRPC to androgen receptor signaling inhibitors (ARSI) was analyzed in 50 subjects. Staining optimization and specificity revealed clear expression of acetyl-p300, acetyl-H3K18, and SIRT2 on CTCs (CK positive, CD45 negative cells). Exposure to A-485, a selective p300/CBP catalytic inhibitor, reduced p300 and H3K18 acetylation. In CRPC patients, a-p300 strongly correlated with its target acetylated H3k18 (Pearson's R = 0.61), and SIRT2 expression showed robust negative correlation with a-H3k18 (R = −0.60). A subgroup of CRPC patients (6/11; 55%) demonstrated consistent upregulation of acetylation based on these markers. To examine the clinical impact of upregulation of the CBP/p300 axis, CRPC patients with reduced deacetylase SIRT2 expression demonstrate shorter response times to ARSI therapy (5.9 vs. 12 mo; p = 0.03). A subset of CRPC patients demonstrate increased p300/CBP activity based on a novel CTC biomarker assay. “With further development, this biomarker suite may be used to identify candidates for CBP/p300 acetylation inhibitors in clinical development.” Read the full study: DOI: https://doi.org/10.18632/oncotarget.28477 Correspondence to: David F. Jarrard - jarrard@urology.wisc.edu Keywords: prostate cancer, circulating tumor cells, p300/CBP About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28477 For media inquiries, please contact: media@impactjournals.com.

Drs. Rana McKay and Jonathan Rosenberg highlight key advances in genitourinary cancers featured at the 2023 ASCO Annual Meeting, including the THOR study in mUCC, VESPER in muscle-invasive bladder cancer, CONTACT-03 in mRCC, and TALAPRO-2 in mCRPC. TRANSCRIPT  Dr. Rana McKay: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Rana McKay, your guest host for the podcast today. I'm a GU medical oncologist at the Morris Cancer Center at the University of California in San Diego and an associate professor at the University of California in San Diego School of Medicine. Joining me today is Dr. Jonathan Rosenberg, the chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center in New York. We'll be discussing practice-changing studies and other key advances in genitourinary cancers that were featured at the 2023 ASCO Annual Meeting.   You'll find our full disclosures in the transcript of this episode, and disclosures of all guests featured on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod.  Jonathan, it's great to have you with us today. How are you?  Dr. Jonathan Rosenberg: I'm doing very well. Thanks so much for hosting today.  Dr. Rana McKay: Oh, of course. It's always fun to step back from ASCO and reflect on all the practice-changing and practice-informing studies that were presented.  Dr. Jonathan Rosenberg: Absolutely.  Dr. Rana McKay: Maybe we can dive right in with LBA4619. This is the much-talked-about THOR study of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select FGFR alterations. What are your key takeaways from this study?  Dr. Jonathan Rosenberg: It is indeed a study we've been waiting for, for quite some time, to see the results in the confirmatory study after the accelerated approval of erdafitinib. This is half of the THOR trial. There were 2 cohorts of patients. One cohort were patients who previously received a checkpoint inhibitor randomized to chemotherapy or erdafitinib, and those data were reported at ASCO this year. The other cohort was randomized against a checkpoint inhibitor in patients who have not received a checkpoint inhibitor, and we'll see those data in a future meeting.   The bottom line for the THOR study is that FGFR3 inhibition improved overall survival compared with chemotherapy, and the chemotherapy in this study was a taxane. The overall survival was 12.1 months for erdafitinib compared to 7.8 months for chemotherapy with a hazard ratio of 0.64. This led to the DMC to stop the study and blind the data and cross people over. There was also a PFS advantage. There really weren't a lot of new toxicity signals seen; the usual suspects in terms of mucositis, hyperphosphatemia, diarrhea, dry mouth, and onycholysis.  And so, what it tells us ultimately is that in a patient who's progressed on a checkpoint inhibitor, we can feel comfortable about using erdafitinib knowing it provides a survival advantage in patients who've been previously treated for advanced urothelial cancer and have an FGFR alteration, either an FGFR2 or 3. And hopefully, we'll see more data in the future from the study, maybe not too long in the future from the other part of the study, comparing it to checkpoint inhibition.   Dr. Rana McKay: That's really exciting. I think it's exciting to see the data about the positivity of erdafitinib versus chemotherapy in this context. Looking at the phase 3 data is going to be really important. Looking at the data in the IO naive context is going to be really important. I feel like this sort of reaffirms what we've been doing in clinical practice. But how do you feel that the study is practice-changing?   Dr. Jonathan Rosenberg: I think it gives us reassurance that for these patients, erdafitinib is an appropriate option. There's no randomized data between erdafitinib and other choices, such as sacituzumab, which is also based on an accelerated approval, or enfortumab, which is based on randomized phase 3 trial. But it gives us level-1 evidence. I do wonder whether the comparison against the checkpoint inhibitor may turn out differently, but we'll see. Those data aren't in evidence. And I do think it was interesting that the majority of patients who were enrolled on the trial were PDL-1 low. We'll see what the comparison to a checkpoint inhibitor is like and whether those patients have similar characteristics.  Dr. Rana McKay: Yeah, you're almost kind of selecting for people that were not primed to respond.   Dr. Jonathan Rosenberg: Exactly.   Dr. Rana McKay: Well, that's really exciting, I think. Moving on to localized bladder cancer, Dr. Pfister presented the results of the VESPER trial. That's LBA4507. I think this study was really important. This was a trial that explored dose-dense MVAC with methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine-cisplatin as a perioperative chemotherapy for muscle-invasive bladder cancer. I think there's always been some discussion around these regimens and how they pair up against one another. Can you tell us about these data?   Dr. Jonathan Rosenberg: It's a very interesting study. It was designed back when it was felt that we could not give patients neoadjuvant therapy. And it was designed as either a neoadjuvant or adjuvant approach. Although, in reality, almost everybody who was enrolled in the study got neoadjuvant chemotherapy, which I think speaks to the shift in practice over the last 10 to 15 years towards neoadjuvant rather than adjuvant therapy. It's an interesting trial in that it used a duration of chemotherapy for the MVAC regimen, the dose-dense MVAC regimen that we don't usually use, which is 6 cycles. And functionally, about 40% of patients couldn't make it to 6 cycles and had to stop sooner, versus 4 cycles of q3-week gemcitabine and cisplatin.   And what the data show is that the progression-free survival for the entire intent-to-treat population didn't reach significance. But if you looked at the neoadjuvant population only, there was an improvement in progression-free survival as well as overall survival. So, it's sort of a negative positive trial. Negative for the primary endpoint, but positive for key secondary endpoints. They did a very interesting analysis looking at the number of cycles that patients received regardless of arm, but looking at it by arm. And it's clear from that analysis that the more chemotherapy they got, the better they did.   Although, the flaw in that analysis is that the healthier patients are, the more chemotherapy they're able to tolerate, and therefore that may translate to an improved overall survival irrespective of the amount of chemotherapy. And this was not necessarily a pre-specified analysis. I think some of the statisticians were clutching their chests during the report of this trial, having talked to several afterward. On the other hand, it does say to me that for a fit, younger patient, it is important to consider dose-dense MVAC instead of gemcitabine and cisplatin.   I'll also note, reading the publication from the first part of the trial, that it appears that nobody over 70 was enrolled from everything I could tell. And so, I question the validity of the tolerability of the results for the average 75-year-old that I see in my practice. Although age is not a bright line cut-off for anybody in terms of cancer treatment. But my own experience has been that dose-dense MVAC has been harder to tolerate for a lot of patients in their 70s, whereas I think we should feel quite comfortable giving it to patients in their sixties. And if you ask me how many cycles I would give, I probably wouldn't say 6, for dose-dense MVAC, I would probably say 4.   Dr. Rana McKay: Was there a predilection that there was a more aggressive disease like nodal disease or other things to prompt the 6 versus 4?  Dr. Jonathan Rosenberg: I think that they stopped primarily for toxicity reasons, but it wasn't clear to me that it was a disease-based issue. And for the neoadjuvant therapy, everyone was supposed to be clinically node-negative on entry, so that probably wouldn't have explained it.  Dr. Rana McKay: Very exciting. I know that the data were quite provocative, but I think it's always difficult to interpret these sorts of subgroup of subgroup analyses, and there's a lot of bias in why people may get more versus less. And I think trying to reduce these data to clinical practice is going to be really important, as you've stated.  Dr. Jonathan Rosenberg: Rana, I'd also like to talk about some key advances in renal cell carcinoma that were reported at ASCO. Dr. Choueiri presented data on LBA4500, the CONTACT-03 study, which really was the first study of its kind in solid tumors because it addressed a major question in the kidney cancer field and in other fields: Is there a role for immunotherapy rechallenge after progression on immunotherapy? Specifically, the study looked at the efficacy and safety of atezolizumab plus cabozantinib versus cabozantinib alone after progression with prior immune checkpoint inhibitor therapy in metastatic RCC. I'd like you to tell me what you think of this study and the results and how they may affect our practice.   Dr. Rana McKay: Absolutely. This was a critically important study looking at the role of IO post-progression on IO. It was a large phase 3 trial that enrolled patients with clear cell and non-clear cell patients. It actually allowed patients with papillary RCC, unclassified RCC, to enroll in the study, whereas most of these studies are excluding patients with non-clear cell disease. Patients had to have progressed on an immune checkpoint inhibitor given either as adjuvant first line or second line, given either as a single agent or in combination with one of the other combos, whether a VEGF or IO. And patients were randomized one-to-one to receive the combination of atezolizumab plus cabozantinib versus cabozantinib alone. And the dosing of the cabozantinib here is at 60 milligrams in the combination, which is the standard dosing of cabozantinib monotherapy. And the primary endpoints for the trial included PFS and OS.   And in essence, this trial was a completely negative study. The primary endpoint, which was centrally reviewed, rPFS, was negative. The hazard ratio there was 1.03. Overall survival was also negative with a hazard ratio of 0.94. And when you look at the subgroup analyses, there really wasn't any specific subgroup that seemed to derive any benefit, potentially those that had a prior response to an immune checkpoint inhibitor, but in essence, a negative study.   And I think these data are really informative because the discussion at ASCO was conducted by Dr. David Braun, and he actually had conducted a very highly scientific Twitter poll to help guide how to interpret the data and what people do. And from that, about 30% of individuals that completed the poll were actually layering on IO therapy, and continuing IO therapy after somebody progressed on therapy layering in a TKI while keeping the IO backbone going.   And I think what this study proves is that we really don't have any really robust data to guide doing that at the present time. And what we may end up doing is compromising the efficacy of the oral TKI or dose-compromising the oral TKI to try to maintain an ineffective IO. And so, I think at the present time these data, while negative, were truly practice-informing. There are other studies that are looking at this strategy as well. I think one of the criticisms here is that atezolizumab really has not had a great track record in renal cell carcinoma in every single context where it was tested, either alone or in combination. It has not met its primary endpoint and it's not utilized as a treatment in RCC. So, there's some discussion that could this be the fact that this is a PDL-1 inhibitor and that it's atezolizumab. And additionally, I think the thing to point out for is that in the modern era if we look at the cabozantinib control arm, cabozantinib in the refractory setting had a PFS of 10.8 months, which is pretty impressive for a later line PFS, if you will. So, there is another study currently ongoing called the TiNivo-2 study that's looking at tivozanib plus nivolumab versus tivozanib alone in a similar patient population. That trial is enrolling only clear cell patients that had progressed on prior IO. So, I think we'll have additional data, but very, I think, informative. I think this question comes up in a lot in other tumor sites as well because of the broad use of checkpoint inhibitors across hematologic and solid tumor malignancies.   Dr. Jonathan Rosenberg: I think this was the most informative negative study and the most negative trial I've seen in a while as well. But it did highlight the importance of asking these questions where people assume they know the answer already, and in fact, we often don't, and our assumptions are wrong. So, I thought that was fascinating and very well described.    Staying in the kidneys arena. I'd like to talk to you also about the phase 2 KEYNOTE-B61, that's Abstract 4518. It looked at first-line lenvatinib and pembrolizumab across non-clear cell carcinomas. Tell me what you thought of the trial and what your takeaways were.   Dr. Rana McKay: This is an important study. I think the treatment of non-clear cell RCC has lagged. I guess the advances have lagged behind clear cell RCC, and really robust phase 3 randomized studies in people with non-clear cell histologies are very limited. This was a single-arm phase 2, so I think we need to kind of take that for what it's worth, that enrolled patients who had non-clear cell RCC per investigator that had received no prior systemic therapy. So, this was a frontline study, and patients received pembrolizumab plus lenvatinib until disease progression or toxicity.   The study enrolled a very robust 158 patients, which is pretty impressive for a modern-day non-clear cell cohort. We've seen data from nivo-cabo that had gotten presented previously by Dr. Lee. That study was a single institution, about 40 patients or so if you will. The primary endpoint of this study was objective response rate, and the bulk of the patients that were enrolled were papillary RCC. As you would imagine, around 60% of patients were papillary. It did include around 18% with chromophobe RCC. And when we break things down by IMDC risk category, about 44% of patients were favorable-risk disease. I think the percentage of patients who were favorable is higher than if we were to take an all-comer metastatic RCC patient population.   But the objective response rate was pretty impressive at 49% with this combination. The CR rate was right around 5.7%. So, I think certainly a pretty solid signal of efficacy. But again, this is a single-arm phase 2 study. I think what's also really interesting, and I think we have to take subset analyses with a grain of salt if you will, but there were responses that were seen across all histologies. And the prior nivo-cabo study that I had shared with you had previously done a futility analysis for patients with chromophobe RCC, and that cohort actually closed down. And in this study, the response rate for the chromophobe patients, though it wasn't a lot of patients, 29 patients with chromophobia RCC, was around 27.6%, so I think these data are certainly informative. If you look at the waterfall plot, there were some deep responses that were certainly observed, and the bulk of patients had some degree of tumor shrinkage with very little patients that had primary PD.   Dr. Jonathan Rosenberg: It's really provocative. So, are we getting to a point where we might start thinking about randomized trials in the non-clear cell population to try to establish the best standard of care?  Dr. Rana McKay: Well, I think PAPMET2 is currently enrolling patients. That study is looking at the combination of cabozantinib with atezolizumab versus cabozantinib alone for frontline papillary. PAPMET1, which was led by Dr. Pal, I mean, these studies are really magnanimous because it takes all hands on deck to get these patients enrolled because they're few and far between. So, I definitely think we need to be moving in that direction. And I think we need to be moving away from lumping all non-clear cells into one bucket because I think what we're seeing is that, one, the biology of these tumors is very distinct and unique, and they don't all behave the same to any one given therapy. So, we really need to move away from just lumping all non-clear cells into one bucket and try to actually conduct studies for each specific subtype.    Dr. Jonathan Rosenberg: Understood and agree. Let's switch gears for a second and talk about prostate cancer. Can you talk about the data from Abstract 5004, the TALAPRO-2 study of talazoparib and enzalutamide compared to placebo and enzalutamide as a first-line treatment with metastatic CRPC that have HR homologous recombination repair gene alterations?    Dr. Rana McKay: Absolutely. So the TALAPRO-2 study is one of three studies that have looked at the combination of PARP inhibitors with an ARSI in the frontline mCRPC setting. And this trial randomized patients to talazoparib and enzalutamide versus placebo enzalutamide. And again, this was first-line mCRPC. Patients were allowed to have received prior docetaxel or prior abiraterone in the castration-sensitive setting, and the primary endpoint was overall survival.  At GU ASCO this year, we saw the top-line data from TALAPRO-2 first get presented. And what was actually presented at this meeting was the subset of patients that were HRR-mutated only. They had two cohorts: an all-comer cohort that was previously presented, and then now they're presenting the subset of the patients that were HRR-mutated. And I think what we've seen across the board is that the efficacy of PARP inhibitors kind of differs by underlying HRR mutations.     When we look at the entire population of HRR-deficient patients, the study was positive, talazoparib plus enzalutamide resulted in an improvement in rPFS compared to enzalutamide placebo. The hazard ratio there was 0.45. And then when we break things down by selected gene groups, they did this subset analysis in patients with only BRCA1, only BRCA2, only PALB2, only CDK12, ATM CHEK2 if you will. The data are most robust for those patients with a BRCA1/2 alteration with hazard ratios of 0.17, 0.19. Again, this is for rPFS.     But then, when we look at some of these other mutations, like ATM CHEK2, hazard ratios are higher, 0.76, 0.90. So, the effect size really kind of drops off for those non-BRCA1/2 altered HRR genes. But if we look across the different subgroup analyses, the interim OS data for the HR deficient, the time to PSA, time to cytotoxic chemo, all of that favored the combination versus placebo enzalutamide for patients that were HR deficient if we just lumped everybody all together.  Dr. Jonathan Rosenberg: How does this fit into the general landscape around this question with selection versus not selecting for HRR alterations?  Dr. Rana McKay: The data that were presented were for the selected patients, and I think that that's not where the controversy is. I think that the selected patients are the ones that seem to derive the most benefit. It's interesting because in looking at the data from PROpel and the final FDA label based off of the PROpel data, the label is only for BRCA1 and 2 patients and not for all comer HRR. It's even a more restricted label than olaporib monotherapy. So, I think it's going to be interesting. I don't know what the right answer is. I think it's going to be interesting to see how this is going to unfold for TALAPRO-2 and even for MAGNITUDE, if you will, like, how select is the selected population going to be. But at the present time, I think the label is what it is for olaparib plus abiraterone in those BRCA1/2 frontline. My hope is that this population is shrinking because everybody should be getting escalated in the metastatic hormone-sensitive setting, and we shouldn't be having people who are naive to an ARSI in frontline mCRPC.  Dr. Jonathan Rosenberg: Understood and agreed.   Dr. Rana Mckay: Well, thank you so much, Jonathan, for joining me today. It's really been a pleasure kind of going through all of the compelling advances in GU cancers from ASCO. I think it was a really exciting meeting, and thanks for your time. Dr. Jonathan Rosenberg: My pleasure. It's been great to talk to you today.     Dr. Rana Mckay: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.    Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Follow today's speakers:    Dr. Rana McKay  @DrRanaMcKay  Jonathan Rosenberg  @DrRosenbergMSK    Follow ASCO on social media:     @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:    Dr. Rana McKay:   Consulting or Advisory Role: Janssen, Novartis, Tempus, Exelxis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Pfizer, Bayer, Tempus   Dr. Jonathan Rosenberg:   Honoraria: UpToDate, Medscape, Peerview, Research To Practice, Clinical Care Options, Physician Education Resource, MJH Life Sciences, EMD Serono, Pfizer  Consulting or Advisory Role: Lilly, Merck, Roche/Genentech, AstraZeneca/MedImmune, Bristol-Myers Squibb, Bayer, BioClin Therapeutics, QED Therapeutics, Pharmacyclics, GlaxoSmithKline, Janssen Oncology, Astellas Pharma, Boehringer Ingelheim, Pfizer/EMD Serono, Merck Therapeutics, Immunomedics, Tyra Biosciences, Infinity Pharmaceuticals, Gilead Sciences, Hengrui Pharmamedical, Alligator BioScience, Imvax  Research Funding (Institution): Genentech/Roche, Seattle Genetics, Bayer, AstraZeneca, QED Therapeutics, Astellas Pharma  Patents, Royalties, Other Intellectual Property (Institution): Predictor of platinum sensitivity      

Christian Gustafsson och Jesper Hallberg är tillbaka i etern. I dag med: • Namnet på letten som IKO jagar – en älskvärd karriär • Antti Suomela i historisk kontext – kan bli näst bäst i SHL genom tiderna • Recap av Växjö, Timrå och Brynäs • Första segern utan andan i halsen • Riikola? Hur mår han? Senaste nytt driekt från Filander i bussen • Den rättdömda straffen • Hyneks no look-pass • Arsi och Fröberg i LA • Q tränar med J20 • Mikko Manner: "Det är ett målgörningsspel" • Analys: Varför vinner IK borta, men inte hemma ...med mera!

Our guests this week are Erin Frey, DVM, MPH, DACVPM, and Jennifer Granick, DVM, MS, PhD, Diplomate ACVIM (SAIM). We all got into veterinary medicine to make a difference – for one animal at a time in most cases – and sometimes it can be hard to remember that the little things we do and recommend can make a world-changing difference. Erin Frey, DVM, MPH, DACVPM, chair of the task force behind the 2022 AAFP/AAHA Antimicrobial Stewardship Guidelines, and Jennifer Granick, DVM, MS, PhD, Diplomate ACVIM (SAIM), task force member, are here to remind us of the effect small actions can make in the face of a very, very big problem. Whether it's never skipping that ear cytology even if you're running late, always having the conversation about topicals even when you're not sure the client will say yes, or being the one to run the diagnostics even when they're used to having refills approved sight unseen, Drs. Granick and Frey are quick to point out that every little bit helps – and when we know better, we can do better.   Find these and all of AAHA's most up-to-date Guidelines, including resources for your clients and team, at aaha.org/guidelines.  Check out all of UMN's antimicrobial stewardship resources at ARSI.umn.edu, including their non-antibiotic prescription pad.  Wish you could watch these conversations? Catch Central Line on YouTube.   Send us feedback or questions anytime at podcast@aaha.org.  This episode was produced by Clear Contender LLC.

Halo, Salam satu Arsi! Di Ngobrol bareng Himars Eps. 8 ini kita akan ngebahas seputar gimana sih 'Magangnya Anak Arsi?' Mulai dari tempat magang anak arsi, relasi dan koneksi, persiapan buat magang sampai culture shock selama magang. Bersama Bang Iqbal sebagai narasumber, yang didampingin juga sama MC kita yang cool abis Ka Uung dan Ka Ingrid. So, stay tuned dan enjoy dengerin NGOBARS sambil nemenin kalian nugas atau gabut! Kita Satu, Arsitektur!

Christian Gustafsson och Jesper Hallberg är tillbaka i etern. En och en halv späckade timmar. Ur innehållet:  • Nytt krautrock-intro till podden • Uppdraget till materialar-Andy och Joel Lundqvist • Jesper och Christian sjunger duett • Genomgång av Växjömatchen • Inför Brynäs och Örebro • Analys av spelarlönerna i IKO • Hur uttalas bob hund och vad är Fishtown för namn? • Recension av nya IK-introt • Arsi och morgonhockeyn • Duuudrrrutt Oskarshamn ...och mycket mer!

Halo, Salam satu Arsi! Di Ngobrol bareng Himars Eps. 7 ini kita akan ngebahas seputar Architecture life as a student. Mulai dari relationship antar teman, relasi dan koneksi, bahkan hal-hal toxic yang terjadi di kehidupan perkuliahan. Bersama Ned dan Juan sebagai narasumber, ditemenin juga sama MC kece kita Ka Bima dan Ka Tata. So, stay tuned dan enjoy dengerin NGOBARS sambil nemenin kalian nugas atau lagi gabut! Kita Satu, Arsitektur!

În episodul 219 al podcastului „Un român în Londra” am vorbit despre marea arșiță a lui 2022, cu temperaturi de peste 35 de grade la orizont, și despre covidul care nu mai pleacă.   Show notes: manuelcheta.com

COR2ED Medical Education: Dr. Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Timing of ARSI and taxanes for mCSPC' in this GU CONNECT podcast. In this podcast, the experts reflect on how the treatment landscape for mCSPC has evolved over the past 7 years resulting in treatment intensification with ADT plus docetaxel following the CHAARTED and STAMPEDE studies and then more recently the use of ADT and androgen receptor inhibitors including abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).  This has further evolved with the recent reporting of the PEACE 1 and ARASENS trials which demonstrated a survival benefit with triplet therapy with abiraterone and darolutamide respectively, being used in combination with ADT and docetaxel. The experts discuss the importance of balancing benefit against risk for their mCSPC patients but state that the triplet therapies appear to be well tolerated in both the PEACE 1 and ARASENS trials. They provide their views, Neal as a urologist and Tanya as a medical oncologist, on the things to consider when making treatment decisions for these patients such as comorbidities, age, performance status, de novo versus recurrent disease, amongst others. They finish by concluding that treatment intensification should be implemented as standard of care for mCSPC patients to enable patients to have as many treatments with different mechanisms of action as early as possible in their treatment journey. 

Halo, salam satu Arsi! Di Ngobrol Bareng Himars Eps.6 kali ini kita bakal ngebahas sepenting apa sih public speaking bagi mahasiswa arsitektur? Kita juga bakal membahas tips and trick untuk ningkatin public speaking temen-temen nih, ditemani dengan narasumber kita Rezi Megananda (Binusian 2023) dan MC yang ga kalah keren, Aliya Danish Ara! Stay tuned dengerin NGOBARS sambil nemenin nugas kalian! Kita Satu, Arsitektur!

Halo, salam satu Arsi! Di Ngobrol Bareng Himars Eps.5 kali ini kita akan ngebahas salah satu stereotip mahasiswa Arsitektur yaitu deadliner, mulai dari serba serbi deadline sampai tips bagi kamu yang deadliner bareng Bima dan Uung yang dipandu oleh Rere! Stay tuned dengerin NGOBARS sambil nemenin UTS dan ngabuburit kalian! Kita Satu, Arsitektur!

Hoy reflexionamos sobre las metas que no hemos podido hacer realidad y buscamos maneras de lograrlas.En este episodio hablamos de:Cómo establecer metas y objetivosTécnicas para alcanzar metasPerder el miedo a soñarSi quieres conocer más de Despertando Podcast síguenos en nuestras redes sociales:Instagram: https://www.instagram.com/despertandopodcast/ Facebook: https://www.facebook.com/despertandopodcast TikTok: https://www.tiktok.com/@despertandopodcast YouTube: https://www.youtube.com/c/DespertandoDurmiendoPodcast Si quieres conocer más sobre nuestros podcasts visita https://www.dudasmedia.com/ See acast.com/privacy for privacy and opt-out information.

Halo, salam satu Arsi! Di Ngobrol Bareng Himars Eps.4 kali ini kita akan ngebahas peran relasi dari berbagai aspek mulai dari akademik maupun nonakademik bagi mahasiswa bareng Zidan dan Ricky! Stay tuned dengerin NGOBARS sambil nemenin kalian UAS! Kita Satu, Arsitektur!

Halo, salam satu Arsi! Di Ngobrol Bareng Himars Eps.3 kali ini kita akan ngebahas seputar perjalanan tahun 2021 dan pentingnya mental health bagi mahasiswa bareng sama Dea dan Rane! Kira-kira gimana caranya menjaga mental health selama kuliah? Stay tuned dengerin NGOBARS sambil nemenin kalian liburan! Kita Satu, Arsitektur!

Halo, Salam satu Arsi! Di Ngobrol Bareng Himars EPS 2 kali ini kita akan ngebahas seputar pindah jurusan bersama kedua narasumber kita yaitu Ahmad dan Wildan yang pastinya punya pengalaman pindah jurusan dan dipandu oleh MC Juan Geraldo. Stay tuned dengerin NGOBARS sambil nemenin kalian nugas dan UTS! Kita Satu, Arsitektur!

Halo, Salam satu Arsi! Di Ngobrol Bareng Himars Eps. 1 kita akan ngebahas seputar organisasi, arsi, dan hati bersama Otniel, Rane, dan Nanda serta dibimbing oleh MC Audree Lumongga. Stay tuned dengerin NGOBARS sambil nemenin kalian nugas! Kita Satu, Arsitektur!

How the late 1800s crated Ethiopian mythology is a counter-ideological resistance to the Haitian RevolutionHaitian Revolution from 1791-1804 vs Abyssinia Adwa in 1896The Haitian revolution put  fear & nightmare in European colonial powers not Abyssinia Ask yourself why was Haiti penalize after its revolution & trapped into debts to the French for decades while Abysinnia after Battle of Adwa got support in nation building from European powers?I always said the Haitian revolution should have been the only symbol of black resistance from the 1800s for the Black diaspora & Africa not AbyssiniaHaiti is a narrative of slaves revoltingAbysinnia is a feudal monarch who enrich themselves from slavery in 1800s Ethiopia is a creation of European colonialism & Battle of Adwa was a proxy war between France & Britain Hati was the real deal not Abyssinia Truly a black nation & an African resistance realizedHaiti narrative is not centered  compared to the promotion of Ethiopia and there is a reason for it The Haitian Revolution has often been described as the largest and most successful slave rebellion in the Western Hemisphere. Slaves initiated the rebellion in 1791 and by 1803 they had succeeded in ending not just slavery but French control over the colony.Haiti had a history of slave rebellions;there were slave rebellions before 1791. poisoning of masters.Before the fighting ended 100,000 of the 500,000 Africans and 24,000 of the 40,000 whites were killed.former slaves managed to stave off both the French forces and the British who arrived in 1793 to conquer the colony, and who withdrew in 1798 after a series of defeats by l'Overture's forces.By 1801 Hait abolished slavery Haitian Revolution had outlasted the French Revolution which ….Napoleon Bonaparte, dispatched 43,000 French troops to capture restore both French rule and slavery. on November 18, 1803the French forces were defeated. On January 1, 1804, Dessalines declared the nation independent and renamed it Haiti. France became the first nation to recognize its independence. Haiti thus emerged as the first black republic in the world, and the second nation in the western hemisphere (after the United States) to win its independence from a European power.The war on Haiti never ended after 1804 but continued in various forms via intervention, coup attempts and continues the management of the Haitian state by disregarding the people demands--compared that with Ethiopia in which from the beggin Europe help create Ethiopia and turn into the first African neo-colonial state with Abyssian as their local administrators and mangaers..Below is the counter narrrative that challanges the mytoolgy around Battle of Adwa being the symbol of restianceMekuria Bulcha, PhD, ProfessorThe circumstances, under which the peoples of the south, such as the Oromo, who were conquered in the 1880s, and the Walaita, who were conquered by Menelik two years before the battle of Adwa, were made to march north and participate in the Battle of Adwa must be notedIt was after Adwa that Menelik imposed the notorious gabbar system on the conquered south. Slavery and the slave trade became even more rampant thereafter with the conquest of the rest of the south and southwest which became hunting grounds for captives and ivory.[29] Ironically, it was the Italian invasion of Ethiopia in 1936 which brought the outrageous institution and evil trade in human beings to an end. “The united country called Ethiopia, which according to Larebo and Borago existed centuries before Adwa, is a myth. The fact is that when he turned north to meet the Italians at Adwa, Menelik was in the midst of the conquest of the south. The entire Macha region – the Gibe and Leeqa states – was annexed only in 1886. Arsi was conquered in 1886 and Hararge in 1887. As indicated above, Walaita was conquered in 1894. The sores inflicted by the atrocities committed against the Oromo at Anole and Calanqoo in 1886 and 1887 by the conquering Abyssinian forces were still bleeding. Even Wallo's conquest in the north was completed in 1878 after years of fierce battles between Menelik (then King of Shawa) and Emperor Yohannes IV on one side and the Wallo Oromo on the other. ““. While the Abyssinians were defending their freedom, the Oromo had no freedom to defend against the Italians. They had lost it to the Abyssinians during the preceding decade.  Their land was an Abyssinian colony. The “contribution” they were forced to make to the war effort saved the Abyssinians from European colonialism, but it did not help them to regain their own independence.”“ the Oromo did not fight at Adwa as ethnic Abyssinians or citizens of Abyssinia as Borago and other commentators try to suggest. They fought for their colonizers. They were not the first people to fight a war for their enemies.”In his Ethiopia: The Last Frontiers, John Markakis writes that Abyssinia “competed successfully in the imperialist partition of the region [Horn of Africa]. Not a victim but a participant in the ‘scramble', Ethiopia doubled its territory and population in a burst of expansionist energy, and thereafter proudly styled itself the ‘Ethiopian Empire'. He notes that “the title [‘Empire'] is not a misnomer, since Ethiopia's rulers governed their new possessions more or less the same way and for similar ends as other imperial powers were doing. The people who took the pride in calling themselves Ethiopians were known also as Abyssinians (Habesha).” Conflict researcher Christian Scherrer notes that “European and Abyssinian colonialism occurred simultaneously, pursued similar interests, albeit from differing socio-economic bases, and this was reinforced by comparable colonial ideologies of the idea of empire and notion of ‘civilizing mission' and the exploitation of the subjugated peoples.” Menelik's colonial conquests, Gebru Tareke, a historian from the north, has also stated that the Abyssinian ruling elite acted like the white colonial rulers in the rest of Africa. The language they used when describing their colonial subjects did not differ from the language the European colonialists were using. It was a language which was infused with stereotypes, prejudices and paternalism. He adds, “They [the Abyssinian elite] tried much like the European colonisers of their time, to justify the exploitability, and moral validity of occupation.” They “looked upon and treated the indigenous people as backward.”[17] One can add here that stereotypes and ethnic slurs about the Oromo, popular in Habesha discourse are the product of this colonial ideology.Margery Perham notes “The speed with which this great extension of the empire was made ….is explained by the …firearms which the emperor [Menelik] was obtaining from France... This same superiority was carrying the European powers at the same speed at the same time from the coast into the heart of Africa.”[18] The Swedish historian Norberg also says that “using the same military technology as the European powers”,[19] Menelik managed not only to conquer the neighbouring African territories, but was also able to garrison them with large forces called naftanya who controlled and lived on the conquered populations. As suggested by Richard Caulk, “the system of near serfdom imposed on wide areas of the south by the end of the nineteenth century could have not been maintained had the newcomers not been so differently armed.[20] The historian Darkwah notes that “Menelik succeeded in keeping the arms out of the reach of the [Oromo] enemy. He did this by imposing a strict control over the movement of firearms into his tributary territories and the lands beyond his frontiers.”[21]Darkwah notes that “in 1877 a Frenchman named Pottier was employed in training a group of Shewan youths in European military techniques. Another Frenchman, Pino, was a regular officer in the army which was commanded by Ras Gobana. Swiss engineers, Alfred Ilg and Zemmerman were employed on, among other things, building bridges across the Awash and other rivers to facilitate movement.”[24]According to Chris Prouty, Colonel Artamonov together with other Europeans was attached to the forces commanded by Ras Tasamma Nadew in Ilu Abbabor. He adds that even Count Nicholas Leontiev, a colonel in the Russian army, was a commander of a force which was sent to conquer the southwest in the 1890s. Another Russian officer, Baron Chedeuvre was Leontiev's second-in-command during the expedition. Several French and Russian medical officers were also attached to the Abyssinian forces, particularly those which were led by Menelik and European commanders. The Russian Cossack Captain Alexander Bulatovich wrote that with him, there were Lieutenants Davydov, Kokhovskiy and Arnoldi along with a command of Cossacks who had finished their term of service” and who were received in audience by Menelik and took leave from him and returned to Russia in June 1898.Genocide was committed not only on the Kaficho. It was also the fate of many of the indigenous peoples in the Omo River Valley, Lake Rudolf region and of the south-western lowlands who were conquered by the Abyssinians in the aftermath of the Adwa victory. Bulatovich, who followed Ras Wolde Giyorgis during his conquest of the territories south of Kafa, writes in his diary-based With the Armies of Menelik II that “By order of the emperor, a fifteen-thousand-man corps, set out on a campaign to annex to the realm of Ethiopia vast lands which lie to the south of it, which no one before this had explored, and which were completely unknown.”although the actual conquest was completed in 1900, the atrocities against the conquered populations did not cease; by and large, slavery and the slave trade continued until the Italian invasion of Ethiopia in 1936. As an Ethiopian historian has stated, Menelik's extension of Ethiopia's frontiers and the incorporation of new areas accentuated “the predatory tendencies of the ruling class and the soldiery. South-western Ethiopia became a hunting-ground for humans as well as animals. Ivory and slaves became the two precious commodities with which traders and adventurers returned from the region.” He wrote that “Members of upper nobility came to have thousands and sometimes tens of thousands of slaves at their disposal.”[9] Giving examples of some of the largest slave owners, the celebrated historian Pankhurst notes that Menelik and Taytu owned 70,000 slaves and Ras Wolde Giyorgis owned 20,000 slaves at the beginning of the twentieth centuryIn 1936, forty years after the Battle of Adwa, the British journalist and author wrote that the “peoples of the south and west were treated with wanton brutality unequalled even in the Belgian Congo. Some areas were depopulated by slavers.”[12] Comparing the harms inflicted by Belgian colonialists in Congo and Abyssinian colonialists in the south, he argued that “The significance of the Congo atrocities is not so much that they were committed as that they were exposed and suppressed.”Haiti is there to remind us the danger of western intervention & management Haiti is there to remind us the danger of NGO-AID intervention & management over the state Haiti is there to reminds us the power of the massesHaiti is truly the symbol of African resistance nowSupport this podcast at — https://redcircle.com/horn-of-africa-leftists/donations

1. Burito - Нирвана 2. Дима Лелюк & Локви - Нас Нет 3. ARSI - Хочу Найти Ту 4. INIMA - Синатра 5. OMANY - Эксперимент 6. Lil Kate - Очень Сильно 7. Cold Carti - Не Выдыхай 8. Рома Зверь - Небо Звёздное 9. Niletto - В Мире Людей 10. Burito - Небеса Суринама 11. NЮ - Без Тебя Фигово 12. Loride - Мчу Мчу Мчу 13. Tesor & Beliy - Последнее Лето 14. Marina Evans feat. Дима Лелюк - Скандал 15. SOM feat. Sofi - Забудь 16. Франциско - Первый Танец 17. Luxor - Солджа 18. Мачете - Кто Здесь Солдат 19. Рома Зверь - Колыбельная Для Взрослых

Possiamo dire che questa sia la Part II (hehe) degli eventi di giugno. Discuteremo sull'attesissimo Cyberpunk e le interessanti demo rilasciate su Steam per l'iniziativa Game Festival. Inizio: Cyberpunk Night City Wire 54:12 Steam Game Festival Conscript, Catchweight Studio Carrion, Phobia Game Studio Inmost, Hidden Layer Games Eldest Souls, Fallen Flag Studio Projection First Light,Shadowplay Studios, Sweaty Chair, Blowfish Studios UltraKill, Arsi "Hakita" Patala (ma che dolce poesia) A Monster's Expediction Through Humans Exhibitions, Draknek & Friends Ghostrunner, One More Level, 3D Realms, Slipgate Ironworks™ Unto the End, 2 Ton Studios Superliminal, Pillow Castle 1:56:45 EA Play (sì, davvero) Intro: https://youtu.be/xSCATnW1TAk Outro: https://www.youtube.com/watch?v=IYyF3MfQRmY Entra nel gruppo Telegram! bit.ly/TryCastTelegram Siamo su... Spotify: bit.ly/TryCastPodcastSpotify iTunes: bit.ly/TryCastiTunes SoundCloud: bit.ly/TryCastSoundCloud Facebook: bit.ly/TryCastFacebook Twitter: bit.ly/TryCastTwitter Instagram: bit.ly/TryCastInstagram Twitch: bit.ly/TryCastTwitch YouTube: bit.ly/TryCastYouTube

Današnja epizoda podcasta se nešto razlikuje od uobičajenih jer se pred vama nalazi prilika da preslušate epizodu podcasta Mladost emitovanu na 10. jubilarnoj MAN konferenciji. Tako su i gost i tema bili specifični i posebni. Ovoga puta ugostile smo (ili je on ugostio nas) Vojkana Arsića, osnivača i direktora Centra E8. Kada smo razmišljale koga bismo mogle da ugostimo na MAN-u 2020, odgovor se nametnuo sam, a i postojalo je mnogo stvari koje smo oduvek želele da ga pitamo. Razgovor je počeo neminovnim spojem aktivizma i pozorišta, kao specifičnosti koja odlikuje Vojkanov rad sve ove godine. Nije nimalo jednostavno biti radnik u kulturi, naročito u ovim vremenima, kada se svi snalaze i poušavaju da opstanu. Zato su, za Vojkana, aktivizam i pozorište nerazdvojivi. “DESI SE NEKAD BURNOUT, A JA SAM SREĆAN ŠTO SAM I U TIM TRENUCIMA USPEO DA PRONAĐEM KANALE I BAVIM SE STVARIMA KOJE ME ZANIMAJU” Razgovarali smo i o odnosu Reflektor teatra i Centra E8, organizacije koja je nastala i rasla na dva bitna stuba – edukaciji i umetnosti. Međutim, nekad je lakše razdojiti stvari i projekte, dati šansu da se uspotavi novi brend koji će, neopterećen ničim drugim osim svojim radom, stvarati predstave koje svi volimo – poput Muškarčina, Sumnjivog lica, Urednika, Crvene… Tako smo se dotakli i jedne od najomiljenijih predstava, predstave Muškarčine koja se igra već osam godina, i koja svaki put prolazi kroz transformacije zajedno sa glumcima koji je igraju, ali uvek ostaje – relevantna. “MISLIM DA TREBA DA PROĐE JOŠ MNOGO GODINA, DA NAM PREDSTAVA O MASKULINITETU NE BUDE VIŠE POTREBNA. TOLIKO GODINA, DA MISLIM DA JA TO MOŽDA NEĆU NI DOŽIVETI. Za Vojkana, siguran prostor je onaj gde je njegov pas, Brat – kolega, miljenik i ravnopravni član E8 zajednice. Međutim, siguran prostor predstavlja i MAN konferencija, pa smo u drugom delu razgovora pričali baš o njoj. MAN je u svojih deset godina postojanja uspeo da okupi mnoge značajne govornice i govornike, pruži platform za učenje svim aktivistkinjama, aktivistima I omladinskim radnicama i radnicima. A čitava priča počela je jednim sastankom i pozivom da se Centar E8 pridruži projektu koji će sa dečacima raditi na pitanju rodne ravnopravnosti. “DOŠAO SAM U KANCELARIJU I REKAO TIMU ‘LJUDI, ZOVU NAS DA RADIMO PROJEKAT O RODNOJ RAVNOPRAVNOSTI, ALI SA MUŠKARCIMA, PROSTO DA NE VERUJETE'. I STVARNO SMO SE ZAPITALI, KAKO SAD DA RADIMO SA MUŠKARCIMA, KAD SE UVEK NA TIM PITANJIMA RADILO SA ŽENAMA”. Nekoliko godina kasnije, rad sa mladićima postao je zašttini znak Centra E8. “Ako su dečaci deo problema, moraju biti i deo rešenja” logika je koja stoji iza ovog rada, često osporavanog i nipodaštavanog. Ali, u ovom trentku, Centar E8, I to, kako Vojkan naglašava, čitav tim Centra E8 uspeo je da se uspostavi kao važan saveznik feminističkoj borbi. A ništa od ovoga ne bi bilo moguće, da u ideju i organizaciju, od početka, nisu verovale tri žene – Marina Blagojević Hughson, Zorana Antonijević i Marina Starčević Cviko. Vojkan je sa nama podelio svoju omiljenu muziku iz predstave, i to baš ove, najnovije produkcije – Urednika, koja govori o fenomenu post-istine i medijkih manipulacija. Sa Vojkanom smo razgovarale i o mnogim drugim temama, poput samog rada na predstavama, a usput nam je otkrio i kako je Centar E8 dobio ime. Preslušajte novu epizodu podcasta Mladost, ili je pogledajte, obzirom da smo ovaj put imale priliku da budemo i u video formatu. Podcast Mladost se bavi mentalnim zdravljem i emocionalnom dobrobiti mladih, pitanjima nasilja, odnosno nenasilja, opresivnim strukturama poput rasizma, seksizma i ekstremizma, kao i pokušajima njihove prevencije. Podcast treba da ohrabri i osnaži mlade da u svakoj prilici ispolje svoje potencijale, i tako postanu heroine i heroji svojih života i svojih zajednica. Voditeljke podcast-a su Jana Šarić i Tamara Urošević.

7even0clock is joined by spiritual enthusiast and connoisseur of positive energy Arsi Bragagnini. Together they discuss a wide variety of topics surrounding the power of the mind and the importance of maintaining your own good energy. They also dive into the contrast between ancestral knowledge and that of the knowledge we have now, from psychedelic drugs to extraterrestrial contact. Arsi give plenty of "gems" what it truly means to manifest and allow miracles to happen.

En dryg timme intensivt IKO-snack: • Frölundamatchen – går den att slå? • Ska Åhlund vara kvar eller lämna redan nu? • Han är IKO:s huvudspår som ny tränare. • Arsi-hyllning. • Inför Leksand – hetare blir inte en match. Med mera!

Arsi Keva on kuvataiteilija ja Ultraääni-levymerkin CEO. Jakso äänitettiin Arsin kotona, Tampereella, 21. elokuuta 2019. Äänen jälkikäsittely: Anssi Alajuuma. 

Simpatica entrevista en Gatas por la Noche con el Bachatero Dominicano Arsi Rey en Gatas por la Noche

Hoy en Gatas por la Noche una simpática entrevista con el cantante Bachatero Arsi Rey 'El tigre dominicano

Pada podcast episode kali ini gw bersama Rifanti ( Mahasiswi Kırklareli Ünivesitesi ) akan membahas tentang gimana caranya menjadi muslim yang baik di tengah arus sekulerisme, yang dimana di kota Kırklareli sendiri masih banyak penduduknya yang sekulerisme walaupun agama mereka adalah islam dan kita yakin itu bukanlah suatu hal yang mudah bagi kita untuk mempertahankan identitas kita sebagai seorang muslim karena mungkin pada suatu waktu kita akan terbawa arus sekulerisme itu sendiri. Oke langsung aja nggak usah berlama lama cekidot listen in Banggabut Podcast and Selam Gabs.

Ickedickedoa – numera en podd om SHL – är tillbaka i etern. Christian Gustafsson och Johnny Larsson dissekerar allt som hänt sedan IKO gick upp och siar om vad som kommer att hända. • Gedigen genomgång av samtliga nyförvärv? • Resonemang kring spelarna som lämnat? • Vad tror vi om spelarna som ryktas till IKO? • Jake Newtons Ulf Dahlén-skills! • Vem ska bli målvakt? • Vad händer med Arsi Piispanen?

Christian Gustafsson, Johnny Larsson och Jonatan Bergöö började dagen i Oskarshamn – med poddmicken i högsta hugg. Ni får följa OT:s utsända i bilar, på flygplatser, på flygplan och där tänkas kan. Det blir ett purfärskt poddavsnitt med spekulationer inför kvällen, diskussioner om Arsi bara borde spela PP och senaste nytt. Dessutom dyker Expressens silly season-kung Johan ”Mr Madhawk” Svensson upp i slutet av podden och ger sina tankar inför kvällen. Håll till godo!

This talk contradicts the longstanding reading of Emerson as invested in idealism and instead charts his obsession with matter both organic and inorganic, organized and unorganized. By attending to his interest in sciences of life, Branka Arsić reconstructs the geological and botanical theories that led him to formulate a genuinely vitalist ontology; and by outlining his vitalism through readings of both early and late essays and lectures, Arsić will ultimately be asking what the ethical and political consequences of his vitalism are. Branka Arsić specializes in literatures of the 19th century Americas and their scientific, philosophical, and religious contexts. She is the author, most recently, of Bird Relics: Grief and Vitalism in Thoreau (Harvard University Press, 2016). Learn more about Harvard Divinity School and its mission to illuminate, engage, and serve at hds.harvard.edu/.

Kunstnike Liit taasavas ARSi maja * Kunstnike Liit taasavas ARSi maja Tallinnas Pärnu maanteel.

Dr Brian Mac Cuarta at the 2018 Tudor and Stuart Ireland Conference: 'Tithes and denominational change in the 1590s: a Wexford woman's dispensation'.

This week the ladies sip on a nice white wine and talk Grammy Awards, Kim K's NSFW photos, and receive skin care routine tips from Arsi.

Dr Brian MacCuarta (Archivum Romanum Societatis Iesu) at the 2016 Tudor and Stuart Ireland Conference. The Impact of the Nine Years War on the continental Irish: Henry Piers in Rome and Spain.

The Gathering Place Church